Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic: GEMO position paper.


Journal

Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 31 03 2020
revised: 01 04 2020
accepted: 02 04 2020
pubmed: 16 4 2020
medline: 16 4 2020
entrez: 16 4 2020
Statut: epublish

Résumé

The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic. All indications and treatment modalities must be re-discussed. This is particularly the case for radiotherapy of bone metastases for which it is possible to reduce the number of sessions, the frequency of transport and the complexity of treatments. These changes will have to be discussed according to the organization of each radiotherapy department and the health situation, while medical teams must remain vigilant about the risks of complications of bone metastases, particularly spinal metastases. In this short piece, the members of the GEMO (the European Study Group of Bone Metastases) offer a number of recommendations to achieve the above objectives, both in general and in relation to five of the most common situations on radiation therapy for bone metastases.

Identifiants

pubmed: 32292693
doi: 10.1016/j.jbo.2020.100291
pii: S2212-1374(20)30046-4
pii: 100291
pmc: PMC7152868
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100291

Informations de copyright

© 2020 Published by Elsevier GmbH.

Déclaration de conflit d'intérêts

All autors declare no conflict of interest.

Références

Radiother Oncol. 2016 Oct;121(1):138-142
pubmed: 27524407
Clin Spine Surg. 2017 May;30(4):156-163
pubmed: 28437329
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
J Neurosurg Spine. 2016 Nov;25(5):646-653
pubmed: 27341054
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):528-37
pubmed: 15145173
Global Spine J. 2017 May;7(3):272-279
pubmed: 28660111
J Neurosurg Spine. 2017 Sep;27(3):295-302
pubmed: 28598293
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):597-599
pubmed: 32199941
Eur J Cancer. 2018 Nov;104:81-90
pubmed: 30336360
J Natl Compr Canc Netw. 2020 Mar 20;:1-4
pubmed: 32197238
Radiat Oncol. 2018 Feb 8;13(1):21
pubmed: 29422106
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):965-76
pubmed: 21277118
Pract Radiat Oncol. 2017 Jan - Feb;7(1):4-12
pubmed: 27663933
JAMA. 2019 Dec 3;322(21):2084-2094
pubmed: 31794625

Auteurs

Sébastien Thureau (S)

Radiation department, Center Henri Becquerel, Quantif-Litis EA 4108, University of Rouen, Rouen, France.

Jean Christophe Faivre (JC)

Radiation department, Institut de Cancérologie de Lorraine - Alexis-Vautrin, Vandœuvre-lès-Nancy, France.

Richard Assaker (R)

University Department of neurosurgery, Lille University Hospital, Lille, France.

Emmanuel Biver (E)

Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Cyrille B Confavreux (CB)

INSERM UMR 1033 - University of Lyon, Bone Metastasis Expert Center (CEMOS) Cancer Institute of Hospices Civils de Lyon, Rheumatology Department, Centre Hospitalier Lyon Sud, Pierre Bénite, F- 69310 France.

Françoise Debiais (F)

Rheumatology department, CHU Poitiers, Poitiers, France.

Martine Duterque-Coquillaud (M)

CNRS UMR9020, INSERM UMR1277, University of Lille, Institut Pasteur de Lille, CHU Lille, France.

Francesco Giammarile (F)

Nuclear Medecine LUMEN, Centre Leon Berard, Lyon, France.

Dominique Heymann (D)

Institut de Cancérologie de l'Ouest, University of Nantes, Inserm, CRCINA, Saint-Herblain, France.

Frédéric E Lecouvet (FE)

Institut du Cancer Roi Albert 2, Cliniques Universitaires Saint-Luc, Service de Radiologie et d'Imagerie Médicale, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Laetitia Morardet (L)

Oncology Department, Pitié Salpêtrière Hospital, Paris, France.

Frederic Paycha (F)

Nuclear Medicine Department, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Jean-Jacques Body (JJ)

Department of Medicine, CHU Brugmann, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Marie-Hélène Vieillard (MH)

University department of Rheumatology, Lille University hospital; Oscar Lambret Center; CNRS UMR9020, INSERM UMR1277, University of Lille, Institut Pasteur, Lille.

Classifications MeSH